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Abstract
An ‘intrinsically disordered protein’ (IDP) is assumed to be unfolded in the cell and perform its biological
function in that state. We contend that most intrinsically disordered proteins are in fact proteins waiting
for a partner (PWPs), parts of a multi-component complex that do not fold correctly in the absence of
other components. Flexibility, not disorder, is an intrinsic property of proteins, exemplified by X-ray
structures of many enzymes and protein-protein complexes. Disorder is often observed with purified
proteins in vitro and sometimes also in crystals, where it is difficult to distinguish from flexibility. In the
crowded environment of the cell, disorder is not compatible with the known mechanisms of protein-
protein recognition, and, foremost, with its specificity. The self-assembly of multi-component complexes
may, nevertheless, involve the specific recognition of nascent polypeptide chains that are incompletely
folded, but then disorder is transient, and it must remain under the control of molecular chaperones and
of the quality control apparatus that obviates the toxic effects it can have on the cell.
Introduction
Flexibility and disorder are two different concepts. When
it applies to a polypeptide chain that has hundreds of
internal degrees of freedom, flexibility describes con-
certed changes that affect a few degrees of freedom,
modifying the overall structure without destroying it.
Disorder implies a lack of constraints on many or all the
degrees of freedom of the chain and no permanent
structure, but the flexibility of proteins is intrinsic, part of
their function, and an essential feature of molecular
recognition. Many X-ray structures, some going back to
the early 1970s, illustrate how a protein can adjust its
conformation while making specific interactions with a
ligand. Disorder does occur in the test tube, as purified
polypeptides are seen to lack a permanent structure. The
concept of “intrinsically disordered proteins” (IDPs)
assumes that the lack of structure also occurs in the cell,
and that a disordered polypeptide is capable of specific
molecular recognition and performs a viable biological
function [1-7]. The evidence is currently scant for both
assumptions. In vivo, most proteins are part of oligomeric
assemblies and multi-component complexes, and the
disorder observed with purified polypeptides in vitromay
result from the absence of other components. On the
other hand, disorder-order transitions are sometimes
observed both in the crystal and in solution when two
proteins form a complex. In such cases, accepted
mechanisms of protein-protein recognition may account
for observed kinetics of the association reaction, but they
do not explain its specificity in the crowded environment
of the cell. Nevertheless, disorder must occur in vivowhen
polypeptide chains are being synthesized, and it may
represent a serious obstacle to the self-assembly of multi-
component complexes. The concept of IDP provides no
plausible model for that process, and we suggest that
most, if not all, IDPs are in fact PWPs (proteins waiting
for a partner) protected from promiscuous interactions
by chaperones and subject to the quality control
apparatus of the cell until they meet their cognate
partners.
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IDPs are (mostly) artifacts of current methods
of protein production
In the last twenty years, the great majority of proteins
used in biophysical and structural studies have been
over-expressed from cloned DNA fragments in Escher-
ichia coli or another expression host. The procedure,
standard in structural genomics, has obvious limitations
in spite of its success. The target protein may be part of a
hetero-complex or a multi-component assembly in the
source organism, where it interacts with other polypep-
tide chains, nucleic acids, or prosthetic groups. These
components are absent, or at least not over-expressed, in
the expression host, and the target may not fold properly
without making these interactions. The long tail seg-
ments present in many ribosomal proteins illustrate the
case: they are disordered in the purified protein but fully
ordered in the ribosome, where interactions with the
RNA determine their conformation [8-9].
Genome-wide studies of protein-protein interactions by
genetic (yeast two-hybrid) and analytical (tandem-affinity
purification coupled to mass spectrometry) methods
indicate that a majority of eukaryotic proteins are part of
hetero-complexes coded by more than one gene. In the
yeast Saccharomyces cerevisiae, at least 70% of the proteins
involved in transcription and translation are known to be
part of assemblies that contain an average of 4.7
components [10], and the list is still far from complete.
When we launched the Orsay Yeast Structural Genomics
pilot-program in 2001, we knew hetero-complexes to be a
problem, though not to what extent. In fact, of the 208
S. cerevisiae open reading  frames (ORFs) that we selected as
targets, 75% were expressed at a satisfactory level in E. coli,
but only 25% could be purified in a soluble form. Nearly
half of those gave crystals of some sort, but few were
suitable for structure determination [11-12]. The low yield
of the purification procedure and the poor quality of the
crystals suggested that many of our targets did not fold
properly, so we deleted terminal segments that sequence-
based procedures predicted to be disordered. The new
constructs were often expressed at a higher level, but only
one in four showed better solubility, and only seven
yielded better crystals [13]. When the pilot-program was
completed in 2005, it had produced a structure for 12
novel proteins, only 6% of the initial set. Yet, the ORF-by-
ORF approach proved fruitful. The procedure developed
for the pilot-program yielded many other X-ray structures
in Orsay, and it could easily be adapted to prepare yeast
hetero-complexes in the frame of the 3D-Repertoire and
SPINE2-Complexes European programs [14-15].
Other structural genomics programs have had a similar
experience on a much larger scale [16]. Expressing
individual eubacterial or archaeal ORFs in E. coli often
yields more soluble proteins (up to 50%) than we got
with yeast. The great majority are homo-oligomers, and
so were most of the yeast proteins we solved. Mamma-
lian proteins, including human, do far worse: less than
10% express as soluble material. Moreover, very few of
the mammalian structures determined by structural
genomics programs (or in other labs for that matter)
are of full-length proteins. Most are fragments, often
single domains cut out of ORFs that are too large for
expression in E. coli or in vitro. Splitting a mammalian
ORF into putative domains yields many constructs that
do not express into soluble proteins, and when some
remain unfolded, it may just be due to all the intra- and
inter-chain contacts that cannot be made.
Flexibility versus disorder in crystals and
in macromolecular recognition
Although a crystal is definitely not the best place to find
disorder, the first sequence-based methods to identify
IDPs relied on features observed in crystal structures
[17-18]. In a Protein Data Bank (PDB) entry, residues that
are present in the sequence, but not the coordinate set,
count as disordered, but to a crystallographer ‘disorder’
only means that the electron density is low, and its atomic
interpretation uncertain. The corresponding atoms either
have a high B-factor or are reported as ‘missing’. The
B-factor measures the mean-square fluctuation of the
atomic position: an atom that moves by 1.25 Å has
B≈120 Å2 and a weak electron density. In the PDB, only
3% of the protein atoms have such high B-factors, because
when a side chain or a chain segment has a weak density it
usually counts as ‘missing’, even though the amplitude of
its movement may be less than the length of a covalent
bond. A low electron density can also mean that the atom
occupies several discrete positions, but this is rarely
reported: in the PDB, alternate positions concern only
0.8% of all protein atoms, almost all of them side chain
atoms. A chain segment with two conformations is likely
to be ‘missing’, albeit far from a state of intrinsic disorder.
Even when a whole domain is ‘missing’, there may be no
actual disorder. An early example is Kol, an immunoglo-
bulin that forms crystals in which only the antigen-
binding Fab moieties are in contact. The Fc moieties are
free to move in the empty space in between, and they lack
electron density even though they are fully structured [19].
The linker peptide, a short polyproline II helix, is flexible
but not disordered either [20].
Kol illustrates how flexibility has been part of protein
crystallography almost from the beginning, and its
functional importance was soon recognized [21]. Whereas
this is now commonplace, other cases dating from the
same early period are still worth citing: hemoglobin,
where flexibility is required for the allosteric transition,
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and the NAD-dependent dehydrogenases. X-ray structures
determined in the 1970s show how the dehydrogenases
change from an open conformation in the absence of the
coenzyme, to a closed one in its presence [22-24]. The
transition, which involves movements of flexible loops
and/or hinge rotations of domains and subunits, remodels
the active site and allows the coenzyme to enter and leave.
Thus, it must play an essential part in the catalytic cycle.
A decade before any 3D structure was known, Koshland
[25-26] had predicted enzymes to be flexible and offered
substrate-induced conformation changes as the answer to
the question: how does hexokinase manage to transfer the
gamma-phosphate of ATP to a sugar hydroxyl and not to
water, equally reactive and much more abundant? X-ray
structures have shown the prediction to be correct for
hexokinase [27], and for many other enzymes. Lysozyme,
ribonuclease A, and chymotrypsin, initially seemed to
prove Koshland wrong, but we now know that their
apparent rigidity is the exception, not the rule (and the
requirement for excluding water does not hold for
hydrolases). Moreover, the flexibility of chymotrypsin
was soon established by a structure of its precursor
chymotrypsinogen [28], from which it differs by the
cleavage of a single peptide bond. The cleavage induces
main chain movements throughout the molecule, includ-
ing the active site and the substrate binding pocket. The
related trypsin/trypsinogen system also displays a large
change in conformation, and, interestingly, two compet-
ing sets of X-ray structures describe it in different ways,
possibly as alternative interpretations of a weak density:
Felhammer et al. [29] see disordered loops in trypsinogen
becoming ordered in trypsin, where Kossiakoff et al. [30]
describe movements between defined positions.
Trypsinogen also illustrates the role of flexibility (or
disorder-order transitions) in macromolecular recogni-
tion: it becomes fully ordered and trypsin-like, when it
binds the pancreatic trypsin inhibitor [31]. In general,
flexibility shows up as conformation changes when
comparing two X-ray structures obtained with and
without a ligand; the ligand can be anything from H+
or a metal ion to DNA or another protein. Disorder-order
transitions are less common, and the disorder may only
be apparent. An early example concerns DNA recogni-
tion by the lactose operon repressor (LacR), a 154 kDa
tetramer. One-dimensional proton nuclear magnetic
resonance (NMR) spectra, albeit unresolved as expected
for a protein this size, contained narrow lines that could
be attributed to the DNA-binding ‘headpiece’ (residues
1-61) [32-33]. The headpiece is folded, but flexibly
connected to the protein body. It is also mobile in
crystals, and it takes a fixed position only in the presence
of the cognate DNA [34]. As a result, the PDB reports it as
‘missing’ in the free repressor (entry 1LBI) but present in
the DNA complex (entry 1EFA). Here again, flexibility
implies no disorder, and its functional role is obvious:
the headpiece can orient itself relative to the DNA double
helix much faster than the rotational diffusion of the
whole tetramer would allow. This would be useless if it
was not properly folded.
Modeling rigid and flexible recognition
Rigid body macromolecular recognition accounts for
the high stability and specificity of antigen-antibody,
enzyme-inhibitor, and many other types of protein-
protein complexes. Its mechanism is relatively well
understood: two complementary protein surfaces come
into contact to form an interface that typically involves
24 residues and buries 800 Å2 of protein surface on each
component [35-36]. In such systems, docking algorithms
that simulate the association of the free components
generally yield good quality models of the assembly
[37-39]. These algorithms take into account a number of
properties, including electrostatics, but shape recogni-
tion is their essential criterion. Their performance
degrades quickly when the molecules change conforma-
tion, and then flexibility must be simulated in order to
generate acceptable solutions [40-41].
The kinetics of association are rather simple in the
absence of conformation changes. A single bimolecular
step is usually observed, and the rate constant (kon) is in
the range 5.104-5.108 M-1s-1 [42], compatible with a
simple diffusion-collision mechanism. The lower bound
of the range corresponds to random collisions that yield
a stable complex if, and only if, the proper regions of the
two protein surfaces happen to face each other. The lock-
and-key model requires in principle the two binding
patches to be perfectly positioned and oriented. It
effectively predicts kon=0 but with more reasonable
assumptions on the geometry of the transition state, kon
evaluates to 105-106 M-1s-1 [43-44], and most enzyme-
inhibitor and antigen-antibody complexes have binding
rates in this range. LacR binds DNAmuch faster than this,
but it undergoes facilitated one-dimensional diffusion
along the double helix, a mechanism applicable only to
DNA recognition [45-46]. Long-range electrostatic inter-
actions modulate binding rates in a way that can be
modeled from the charge distribution on the protein
surfaces [44,47-49], and that quantitatively explains
most of the larger kon values reported in [42].
Flexibility adds a level of complexity to the binding
process. Conformation changes and disorder-to-order
transitions are expected to make association slower, but
in a way that is difficult tomodel. A plausiblemechanism
of flexible recognition is conformer selection: a fraction
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of the receptors pre-exist in the correct conformation, and
only those can bind the ligand (‘receptor’ and ‘ligand’ are
here for convenience only). An alternative is induced fit:
most, if not all, of the receptor molecules are able to form
a low affinity complex with the ligand, and the inter-
action promotes the conformation changes that yield the
stable assembly. Both mechanisms predict the binding
kinetics to be biphasic, but the first order step (the
conformation change) is often fast on the time scale of
the experiment, and only one phase is detected. Its rate
should be proportional to the fraction of the receptors
that have the correct conformation, if conformer selec-
tion is the dominant mechanism, and to the probability
that the intermediate evolves into the product before it
dissociates, if induced fit applies.
Kinetic data are available on many systems that involve
conformation changes and a few that display disorder-
to-order transitions. Conformer selection can often be
excluded. For instance, the NAD-dependent dehydro-
genases must be in an open conformation when they
bind the coenzyme, which they do at nearly diffusion-
limited rates. On the other hand, conformer selection
certainly contributes to protein-protein recognition
when the conformation changes are of limited amplitude
[49-51]. However, the observed binding rates either
imply that native-like conformations are highly popu-
lated to start with, or that induced fit coexists with
conformer selection. Thus, induced fit must be the
dominant mechanism when trypsinogen binds pancrea-
tic trypsin inhibitor. The affinity of the precursor for
pancreatic trypsin inhibitor is eight orders of magnitude
less than for trypsin, due to koff increasing by six orders
while kon decreases by only two [52-53]. Conformer
selection would require 1% of the trypsinogen molecules
to preexist in a trypsin-like conformation, whereas the
actual fraction is estimated to be less than one in a
million.
Conformer selection may also involve (partly) disor-
dered proteins. An example is the kinase inhibitory
domain (KID) of the p27Kip1 cyclin-dependent inhibitor.
In solution, KID contains a significant amount of a-helix
detected by NMR and circular dichroism [54]. In crystals
of the ternary complex with Cdk2 and cyclin A (Figure 1),
its N-terminal half is partly helical and interacts with the
cyclin, whereas the C-terminal half forms an open loop
in contact with the kinase [55]. KID has nanomolar
affinity for either Cdk2 alone or cyclin A alone and
remarkable binding kinetics: kon is low (5.10
3 M-1s-1) for
Cdk2 alone, and high (1.6 to 3.106 M-1s-1) for cyclin A
alone. It is also high with the Cdk2-cyclin complex, but
then the reaction is biphasic and the second step as slow
as for Cdk2 alone [54]. Albeit compatible with induced
folding, the kinetics suggest a conformer selection mech-
anism by which the cyclin quickly associates with the
many KID molecules that contain a helical fragment,
while the C-terminal conformation recognized by the
kinase is very rare.
Disorder in vivo: does it exist, and how does
the cell deal with it?
But what is the actual state of KID in the living cell?
There, the overall protein concentration reaches hun-
dreds of grams per liter, orders of magnitude above the
concentrations of the purified proteins in test tube
experiments [56]. As a result, proteins disordered in vitro
may become partially ordered, and this can be tested in
the test tube by adding molecular crowding agents.
These agents have little effect on KID [57], but FlgM, a
97-residue polypeptide that binds the transcription
factor s28, gains structure in their presence. In dilute
solution, FlgM is disordered except for transient
a-helices in its C-terminal half. This half becomes
fully ordered upon binding to s28, while the N-terminal
half remains disordered [58-59]. Adding a high con-
centration of other proteins (bovine serum albumin
or ovalbumin), or glucose, induces structure in the
Figure 1. The p27Kip1-Cdk2-cyclin A ternary complex
In the crystal structure [55] (Protein Data Bank entry 1JSU), the kinase
inhibitory domain of p27Kip1 (KID, in green) is observed to be partly helical
and interact with both the kinase and the cyclin. When it is free in solution,
KID is mostly disordered, but some of the helical structure is already
present [54], making conformer selection a plausible alternative to induced
fit as an explanation of the rapid association with the cyclin.
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C-terminal, but not the N-terminal half. Remarkably, in-
cell NMR shows that the polypeptide over-expressed in
E. coli also has an ordered C-terminal and a disordered
N-terminal half. As E. coli s28 is not over-expressed, an
interaction with it cannot explain that transition, and it
may be induced by the crowded environment in the
cell [60].
If the disorder seen in vitro for KID, FlgM and other
putative IDPs effectively occurs in the cell, it must affect
the stability, the kinetics and the specificity of the inter-
actions that mediate the function of these polypeptides.
A conformation change or a disorder-order transition
costs free energy, and it should make the assembly less
stable. It does in trypsinogen/pancreatic trypsin inhibitor
relative to trypsin/pancreatic trypsin inhibitor, but in
general flexible recognition is associated with the
formation of large interfaces [35], and the additional
interactions must offset that cost. Thus, KID loses over
2800 Å2 of accessible surface area in contact with Cdk2-
cyclin A, four times as much as an antibody in contact
with the cognate antigen. The kinetic constraints could
be of more consequence: the low kon of KID for binding
Cdk2 (as opposed to Cdk2-cyclin A) predicts the binary
complex to form in about an hour at a KID concentration
of 10-7 M, and such a long lag is probably not compatible
with its inhibitory function.
However, the most significant constraint in recognition
is specificity. A disordered polypeptide chain has no
defined shape, and it contains the same chemical groups
as all other proteins, positioned more or less at random
in space. How can it recognize, or be recognized by,
another biomolecule? In a test tube experiment, the
cognate interactions have no (or very few) competitors;
in vivo they have thousands or millions. A linear
sequence motif, or the presence of modified residues
(phosphorylation, for instance), can serve as identifica-
tion in some cases, but in general disorder must imply
promiscuity, and be incompatible with all but a few
cellular functions.
Another argument against this is that promiscuous
interactions can be toxic [61], and cells have efficient
quality control mechanisms designed to prevent them
and to degrade or sequester misfolded polypeptides.
Artificial conditions, such as over-expression in E. coli,
may allow putative IDPs to escape quality control, but
the problem of handling disorder in the cell is more
general. It concerns all nascent polypeptide chains, and,
most of all, those that will form oligomers. Nascent
polypeptides are protected by chaperone proteins as they
exit the ribosome, or sequestered by chaperonins, such as
GroES/GroEL in bacteria, until their folding is completed.
How they assemble to form oligomers is not understood
at present. Their subunits are often unstable in vitro, and,
whether folded or partially unfolded, they carry large
hydrophobic surface patches that are prone to non-
specific interactions. In the cell, their concentration must
be kept low, and their assembly cannot be fast because
it is a second or higher order reaction. With hetero-
complexes, stoichiometry raises an additional question.
It cannot be exact when subunits are independently
synthesized on the ribosome, and the component in
excess is a source of promiscuous interactions. Here
again, the cell protects itself by using chaperones and
protein degradation. Hemoglobin is an example: in beta-
thalassemia, the alpha-chains are produced in excess
of the beta-chains. They cannot form homo-tetramers
(the beta-chains do) and are unstable, but a specialized
chaperone prevents them from releasing heme and
damaging the red blood cells [62]; in precursor cells,
excess alpha-chains are polyubiquitinated and degraded
by the proteasome [63].
Conclusion
The hemoglobin alpha-chain is not an IDP, it is a PWP,
and, as such, it represents a very common situation. We
contend that most, if not all, putative IDPs are in fact
PWPs. They are unfolded in the test tube, but in vivo they
are folded and part of a multi-component assembly
(possibly of more than one). In general, molecular
disorder is not compatible with function. A partly dis-
ordered polypeptide may be capable of specific recogni-
tion through a conformer selection mechanism, but then
it is the ordered population that reacts, and the disorder
is neither intrinsic nor functional. While disorder cannot
be entirely avoided in the cell, it remains transient, and it
is kept to a minimum by sophisticated mechanisms of
biosynthesis and quality control. The mechanism that
limits the damage an improper assembly of hemoglobin
can cause in beta-thalassemia is probably one of many.
Research in the field is very active and highly relevant to
human health, and we may expect more to be discovered
in coming years.
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